Published in Curr Pharm Biotechnol on November 01, 2010
Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res (2014) 2.54
BioAssay Ontology (BAO): a semantic description of bioassays and high-throughput screening results. BMC Bioinformatics (2011) 2.13
Shifting from the single to the multitarget paradigm in drug discovery. Drug Discov Today (2013) 1.28
MScreen: an integrated compound management and high-throughput screening data storage and analysis system. J Biomol Screen (2012) 0.96
DNA-Encoded Solid-Phase Synthesis: Encoding Language Design and Complex Oligomer Library Synthesis. ACS Comb Sci (2015) 0.92
A rare variant in the osteoarthritis-associated locus GDF5 is functional and reveals a site that can be manipulated to modulate GDF5 expression. Eur J Hum Genet (2012) 0.89
Identification of verrucarin a as a potent and selective steroid receptor coactivator-3 small molecule inhibitor. PLoS One (2014) 0.87
High-throughput screening for small-molecule modulators of inward rectifier potassium channels. J Vis Exp (2013) 0.87
Computational prediction and validation of an expert's evaluation of chemical probes. J Chem Inf Model (2014) 0.84
Overcoming scientific and structural bottlenecks in antibacterial discovery and development. Ups J Med Sci (2014) 0.81
Consensus Diversity Plots: a global diversity analysis of chemical libraries. J Cheminform (2016) 0.81
Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer. Clin Cancer Res (2016) 0.79
Scaffold Diversity of Fungal Metabolites. Front Pharmacol (2017) 0.75
PubChem BioAssay. SLAS Discov (2017) 0.75
How many drug targets are there? Nat Rev Drug Discov (2006) 14.22
The druggable genome. Nat Rev Drug Discov (2002) 13.61
Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov (2004) 7.84
NIH Molecular Libraries Initiative. Science (2004) 7.04
Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov (2009) 7.01
High-throughput screening assays for the identification of chemical probes. Nat Chem Biol (2007) 4.50
The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Health Policy (2009) 3.07
A crowdsourcing evaluation of the NIH chemical probes. Nat Chem Biol (2009) 2.29
Target discovery. Nat Rev Drug Discov (2003) 1.77
A guide to drug discovery: Target selection in drug discovery. Nat Rev Drug Discov (2003) 1.70
The application of cell-based label-free technology in drug discovery. Biotechnol J (2008) 1.41
HTS and hit finding in academia--from chemical genomics to drug discovery. Drug Discov Today (2009) 1.32
Cell-based high-content screening of small-molecule libraries. Curr Opin Chem Biol (2007) 1.27
The role of the medicinal chemist in drug discovery--then and now. Nat Rev Drug Discov (2004) 1.22
Luxury accommodations: the expanding role of structural plasticity in protein-protein interactions. Structure (2000) 1.08
Flow cytometry for drug discovery, receptor pharmacology and high-throughput screening. Curr Opin Pharmacol (2007) 1.04
The impact of the completed human genome sequence on the development of novel therapeutics for human disease. Annu Rev Med (2004) 1.02
High-content analysis in preclinical drug discovery. Comb Chem High Throughput Screen (2008) 0.91
Current Screens Based on the AlphaScreen Technology for Deciphering Cell Signalling Pathways. Curr Genomics (2009) 0.91
Drug discovery through industry-academic partnerships. Nat Chem Biol (2006) 0.90
Small-molecule screening: it takes a village... ACS Chem Biol (2007) 0.88
Targetability of human disease genes. Curr Drug Discov Technol (2007) 0.88
RNA interference screening for the discovery of oncology targets. Expert Opin Ther Targets (2009) 0.83
How academia can help drug discovery. Nat Rev Drug Discov (2004) 0.82
SPR imaging for high throughput, label-free interaction analysis. Comb Chem High Throughput Screen (2009) 0.80
Oncogenes and pathway identification using filter-based approaches between various carcinoma types in lung. Int J Comput Biol Drug Des (2009) 1.43
K-Screen: a free application for high throughput screening data analysis, visualization, and laboratory information management. Comb Chem High Throughput Screen (2011) 1.30
Compound ranking based on a new mathematical measure of effectiveness using time course data from cell-based assays. Comb Chem High Throughput Screen (2013) 1.12
Identification of survival genes in human glioblastoma cells by small interfering RNA screening. Mol Pharmacol (2009) 1.11
A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther (2008) 1.10
Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Curr Chem Genomics (2010) 0.96
Development of a fluorescence resonance energy transfer assay for measuring the activity of Streptococcus pneumoniae DNA ligase, an enzyme essential for DNA replication, repair, and recombination. Anal Biochem (2002) 0.96
Designing, optimizing, and implementing high-throughput siRNA genomic screening with glioma cells for the discovery of survival genes and novel drug targets. J Neurosci Methods (2009) 0.95
The University of Kansas High-Throughput Screening laboratory. Part I: meeting drug-discovery needs in the heartland of America with entrepreneurial flair. Future Med Chem (2011) 0.90
Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther (2013) 0.89
Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens. J Pharmacol Exp Ther (2011) 0.88
Alkylation sensitivity screens reveal a conserved cross-species functionome. Mol Cancer Res (2012) 0.87
Synthetic protection short interfering RNA screen reveals glyburide as a novel radioprotector. Radiat Res (2009) 0.87
Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development. Neurosurg Focus (2010) 0.85
Implementation of a high-throughput screen for identifying small molecules to activate the Keap1-Nrf2-ARE pathway. PLoS One (2012) 0.78
Combinatorial Chemistry & High Throughput Screening. Editorial. Comb Chem High Throughput Screen (2013) 0.77
The University of Kansas High-Throughput Screening Laboratory. Part II: enabling collaborative drug-discovery partnerships through cutting-edge screening technology. Future Med Chem (2011) 0.76
Measuring and Statistically Testing the Size of the Effect of a Chemical Compound on a Continuous In-Vitro Pharmacological Response Through a New Statistical Model of Response Detection Limit. J Biopharm Stat (2015) 0.75
Editorial. Comb Chem High Throughput Screen (2012) 0.75
Scientific misconduct. Comb Chem High Throughput Screen (2014) 0.75
To greater heights, from a solid foundation. Comb Chem High Throughput Screen (2010) 0.75
To screen or not to screen: an impassioned plea for smarter chemical libraries to improve drug lead finding. Future Med Chem (2014) 0.75
Editorial: Validate and Verify: Keys to Scientific Excellence. Comb Chem High Throughput Screen (2016) 0.75